the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
August 23, 2019 – Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal viral disease characterized by progressive damage or inflammation of the white matter of the brain at multiple locations (i.e., multifocal). It is caused by the JC virus, after …
Therapies that promote progressive multifocal leukoencephalopathy (PML) Read more »
June 22, 2016 – The European Medicines Agency (EMA) has approved, as of the end of May 2016, Infliximab (Flixabi). Infliximab (Flixabi) is a monoclonal antibody that has been designed to attach to a protein called tumour necrosis factor-alpha (TNF-alpha) and block …
April 15, 2011 – The American Food and Drug Adeministration (FDA) informed today that it continues to receive reports of a rare cancer of white blood cells (known as Hepatosplenic T-Cell Lymphoma or HSTCL) primarily in adolescents and young adults …
November 3, 2009 – As we learn from it’s todays announcement, FDA is requiring stronger warnings about an increased risk of lymphoma and other cancers in children and adolescents who are treated with drugs that block tumor necrosis factor. TNF …
Boxed Warning Updated: TNF Blockers and Cancer Risks in Children Read more »